Back by $6.4 million in private funding, a new Neuroscape Psychedelics Division at the University of California, San Francisco will focus on the delivery of more personalized and precise psychedelic treatments.
Ketamine has been demonstrated to be effective in treating mental health disorders, chronic pain and addiction by causing several developments in key areas of the brain associated with these conditions.
Psychedelic Medicine Association president Lynn Marie Morski, MD, Esq., a Sana Symposium steering committee member, discusses the mission of the Psychedelic Medicine Association, bringing psychedelics education to front-line providers who are…
Findings in a recently published research review could help guide practitioners in future studies to identify patients who are more likely to have adverse reactions to psychedelics and adjust dosages accordingly.
Psych Congress co-chair and researcher Charles Raison, MD, recently spoke with David Van Nuys, PhD, on the Shrink Rap Radio podcast about depression, traditional antidepressants, and psychedelic-assisted psychotherapy.
The use of psychedelics in psychotherapy can help patients go beyond ameliorating symptoms and confront their root causes of depression, Andrew D. Penn, RN, MS, NP, CNS, APRN-BC, and Charles Raison, MD, said at a session at the Psych Congress 2020…
The US Food and Drug Administration (FDA) recently granted Usona Institute, Madison, Wisconsin, the Breakthrough Therapy designation for psilocybin in the treatment of patients with major depressive disorder (MDD).
SAN DIEGO—Psilocybin-assisted psychotherapy appears to have a beneficial and lasting effect on patient mood, but possible approval of the treatment remains some time away, a researcher said at Psych Congress 2019.